Evidence map›Paper›PMID 38096156›Full record

ReviewNeuro-oncology2024

Liquid biopsy in H3K27M diffuse midline glioma.

Jina Patel, Rayan Aittaleb, Robert Doherty, Ananya Gera, Benison Lau, Dana Messinger, Jack Wadden, Andrea Franson, Amanda Saratsis, Carl Koschmann

Open access · hybridAbstract readReview
In one paragraph

Review in Neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Frequency and outcomes of midline gliomas in a tertiary care hospital in Pakistan: a retrospective study.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jina PatelDepartment of Pediatrics, Michigan Medicine, Ann Arbor, Michigan, USA.
Rayan AittalebDepartment of Pediatrics, Michigan Medicine, Ann Arbor, Michigan, USA.
Robert DohertyDepartment of Pediatrics, Michigan Medicine, Ann Arbor, Michigan, USA.
Ananya GeraDepartment of Pediatrics, Michigan Medicine, Ann Arbor, Michigan, USA.
Benison LauDepartment of Pediatrics, Michigan Medicine, Ann Arbor, Michigan, USA.
Dana MessingerDepartment of Pediatrics, Michigan Medicine, Ann Arbor, Michigan, USA.
Jack WaddenDepartment of Pediatrics, Michigan Medicine, Ann Arbor, Michigan, USA.
Andrea FransonDepartment of Pediatrics, Michigan Medicine, Ann Arbor, Michigan, USA.
Amanda SaratsisAdvocate Health Care, Chicago, Illinois, USA.
Carl KoschmannDepartment of Pediatrics, Michigan Medicine, Ann Arbor, Michigan, USA.ORCID 0000-0002-0825-7615
Michigan Medicine · USAdvocate Health Care · US

Funding

PULMONARY CELLULAR AND MOLECULAR BIOLOGY TRAININGT32HL007749 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Pickett Dickson · 1993 to 2026
$19.9M
Training Program in Molecular HematologyT32HL007622 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SUNG WON CHOI, Jordan A. Shavit · 1986 to 2026
$9.2M
Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline gliomaR01NS124607 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Carl J Koschmann · 2022 to 2026
$2.2M
The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade gliomaR01NS119231 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOSCHMANN, CARL J · 2021 to 2025
$1.9M
NHLBI NIH HHS T32 HL007622NHLBI NIH HHS T32 HL007749NIH HHS R01-NS119231NINDS NIH HHS R01 NS119231NINDS NIH HHS R01 NS124607
6 · The paper itself

Abstract

Diffuse midline glioma (DMG) with H3K27M mutation is an aggressive and difficult to treat pediatric brain tumor. Recurrent gain of function mutations in H3.3 (H3.3A) and H3.1 (H3C2) at the 27th lysine to methionine (H3K27M) are seen in over 2/3 of DMGs, and are associated with a worse prognosis. Due to the anatomical location of DMG, traditional biopsy carries risk for neurologic injury as it requires penetration of vital midline structures. Further, radiographic (MRI) monitoring of DMG often shows nonspecific changes, which makes therapeutic monitoring difficult. This indicates a critical need for more minimally invasive methods, such as liquid biopsy, to understand, diagnose, and monitor H3K27M DMG. Here, we review the use of all modalities to date to detect biomarkers of H3K27M in cerebrospinal fluid (CSF), blood, and urine, and compare their effectiveness in detection, diagnosis, and monitoring treatment response. We provide specific detail of recent efforts to monitor CSF and plasma H3K27M cell-free DNA in patients undergoing therapy with the imipridone ONC201. Lastly, we discuss the future of therapeutic monitoring of H3K27M-DMG, including biomarkers such as mitochondrial DNA, mutant and modified histones, and novel sequencing-based approaches for improved detection methods.

Indexed as

Brain NeoplasmsGliomaLiquid BiopsyBiomarkers, TumorHistonesHumansMutationPrognosisBiomarkers, TumorHistonescell-free tumor DNAdiffuse midline gliomaH3K27Mliquid biopsyONC201

Identifiers

PMID38096156
PMCPMC11066927
OpenAlexW4389799395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.